Transforming Patient-Centered Care for HR+/HER2- Breast Cancer Patients Through Collaborative Learning: A Toolkit for Clinical Teams
hosted byPrime Education, LLCTransforming Patient-Centered Care for HR+/HER2- Breast Cancer Patients Through Collaborative Learning: A Toolkit for Clinical Teams is organized by Prime Education, LLC.
Release Date: October 26, 2022
Expiration Date: May 3, 2024
Description:
Advances in the therapeutic landscape for breast cancer have led to new therapies with novel mechanisms of action for HR+/HER2- breast cancer. Understanding and implementing evidence-based use of these therapies, especially for patients at a high risk of recurrence, remains a critical component of HR+/HER2- breast cancer care for which healthcare providers must be prepared.
With new oral oncolytic treatments, the cancer care delivery model is shifting, giving patients and caregivers more convenience and flexibility, but also more responsibility for adherence and adverse event management. This toolkit was developed to guide clinical teams in patient education, and it includes practical tips and resources on therapeutic options, the importance of treatment adherence and persistence, and strategies for monitoring and managing adverse events.
Download the toolkit to access:
• Patient-friendly materials for sustainable patient education and counseling
• Talking points and tips for empowering patients in self-monitoring and self-management
Agenda:
• Understanding HR+/HER2- Breast Cancer
• What Are My Goals for Treatment?
• Oral Therapies for HR+/HER2- Breast Cancer
• How Effective Are Oral HR+/HER2- Breast Cancer Therapies?
• Why Is it Important to Adhere to the Treatment Plan?
• What Are Potential Side Effects?
• When Should I Contact My Doctor?
• Goals and Preferences: Communication With Your Care Team
• Take Action: Create a Plan to Improve Adherence and Manage Side Effects
Learning Objectives:
• Monitor adverse events associated with oral therapies for HR+/HER2- breast cancer treatment to promptly identify and effectively treat side effects
• Assess current practice patterns and barriers to treatment adherence and persistence in HR+/HER2- breast cancer in community oncology settings
• Evaluate principles of patient-centered care and shared decision-making to management decisions in HR+/HER2- breast cancer
• Apply evidence-based strategies for patient education and counseling regarding treatment efficacy, side effect management, and adherence
